<DOC>
	<DOCNO>NCT00686543</DOCNO>
	<brief_summary>The purpose study : explore potential different dose strategy posaconazole oral suspension ( POS ) increase plasma level profile pharmacokinetics dose strategy patient compromise gastrointestinal function high risk Invasive Fungal Infection .</brief_summary>
	<brief_title>Oral Posaconazole High Risk Patients With Gastrointestinal Dysfunction ( Study P05115 )</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Posaconazole</mesh_term>
	<criteria>Subjects &gt; =18 year age High risk poor enteral medication absorption , base effect cytotoxic chemotherapy , evidence , limited , mucositis , nausea , vomit , diarrhea , baseline . High risk invasive fungal infection ( IFI ) base anticipate document prolonged neutropenia ( absolute neutrophil count [ ANC ] &lt; 500/mm^3 [ 0.5 x 10^9/L ] ) . Clinical laboratory safety test within normal limit clinically acceptable investigator sponsor . Free clinically significant disease ( primary hematologic disease ) would interfere study evaluation . Subjects must willing give write informed consent able adhere dose , study visit schedule , mandatory procedure . Female subject pregnant , intend become pregnant , nursing . Excluded prior treatment . Subjects receive systemic antifungal therapy ( oral , intravenous , inhaled ) treatment proven probable IFI within 30 day Enrollment ( ie , voriconazole , fluconazole [ FLU ] , itraconazole [ ITZ ] ) . Subjects receive posaconazole prophylaxis IFI 10 day prior enrollment . ( Subjects receive either voriconazole micafungin prophylaxis IFI discontinue therapy upon enrollment . ) Subjects moderate severe liver dysfunction Baseline , define aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) level great two time upper limit normal ( ULN ) , total bilirubin level great two time ULN . Subjects take prohibited medication recently indicate washout period prior Enrollment . Subjects must take prohibited medication study . Subjects situation condition , opinion investigator , may interfere optimal participation study . Subjects use investigational drug biologic agent chemotherapy regimen within 30 day study entry . Subjects part staff personnel directly involve study . Subjects family member investigational study staff . Prior enrollment study . Subjects history hypersensitivity idiosyncratic reaction azole agent . Subjects Eastern Cooperative Oncology Group ( ECOG ) performance status &gt; 2 prior induction chemotherapy underlying disease . Subjects proven probable invasive systemic fungal infection Baseline . Subjects history acute lymphoblastic leukemia chronic myelogenous leukemia without blast crisis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Antifungal Agents</keyword>
	<keyword>Anti-Infective Agents</keyword>
</DOC>